CYP2C19 Genotyping

The CYP2C19 Genotyping test contains 1 test with 2 biomarkers.

The cytochrome P450 gene products are responsible for metabolizing a large number of widely prescribed drugs. Clopidogrel (Plavix®) is metabolized by CYP2C19 to its active form. Individuals with poor-metabolizers of CYP2C19 will require alternative drug therapy due to inability to activate Clopidogrel (Plavix®), while those with ultra-extensive metabolizer phenotype will require a decreased dosage due to higher than normal rates of drug metabolism.

The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.

Also known as: Clopidogrel (CYP2C19 Genotyping), Clopidogrel Pharmacogenetic Testing, CYP2C19 Sequence Genotype

Cyp2c19 Genotype

Interpretation: